U.S. markets close in 2 hours 54 minutes
  • S&P 500

    3,472.88
    +103.72 (+3.08%)
     
  • Dow 30

    28,186.12
    +706.09 (+2.57%)
     
  • Nasdaq

    11,615.88
    +455.31 (+4.08%)
     
  • Russell 2000

    1,628.99
    +14.70 (+0.91%)
     
  • Crude Oil

    38.94
    +1.28 (+3.40%)
     
  • Gold

    1,894.70
    -15.70 (-0.82%)
     
  • Silver

    23.92
    -0.41 (-1.70%)
     
  • EUR/USD

    1.1714
    -0.0012 (-0.11%)
     
  • 10-Yr Bond

    0.7810
    -0.1010 (-11.45%)
     
  • GBP/USD

    1.2993
    -0.0078 (-0.60%)
     
  • USD/JPY

    104.5980
    +0.0110 (+0.01%)
     
  • BTC-USD

    14,098.71
    +165.56 (+1.19%)
     
  • CMC Crypto 200

    272.93
    +4.34 (+1.62%)
     
  • FTSE 100

    5,883.26
    +96.49 (+1.67%)
     
  • Nikkei 225

    23,695.23
    +399.75 (+1.72%)
     

U.S. FDA staff says effectiveness data to support approval of Biogen Alzheimer's drug

·1 min read

Nov 4 (Reuters) - Biogen Inc's experimental Alzheimer's disease drug was found effective enough in a large trial to support approval, a U.S. Food and Drug Administration panel said on Wednesday, boosting the chances of a swift approval of the drug.

As a next step to a regulatory approval, the drug will be reviewed by FDA's independent experts in a meeting on Friday that will make recommendations to the agency.

U.S. Food and Drug Administration's independent experts will consider the remarks in a meeting on Friday, before making their recommendations to the agency.

A final decision on the drug, jointly developed with Japan's Eisai Co Ltd, is due by March 2021. (Reporting by Manas Mishra and Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)